Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni, P
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). [electronic resource] - HIV medicine Feb 2009 - 116-24 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-1293
10.1111/j.1468-1293.2008.00660.x doi
Adult
Aged
Benzoates--pharmacokinetics
Diketopiperazines
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections--drug therapy
HIV Protease Inhibitors--pharmacokinetics
HIV-1--immunology
Humans
Lopinavir
Male
Middle Aged
Piperazines--pharmacokinetics
Pyrimidinones--pharmacokinetics
RNA, Viral--immunology
Receptors, CCR5--therapeutic use
Ritonavir--pharmacokinetics
Spiro Compounds--pharmacokinetics
Young Adult
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). [electronic resource] - HIV medicine Feb 2009 - 116-24 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-1293
10.1111/j.1468-1293.2008.00660.x doi
Adult
Aged
Benzoates--pharmacokinetics
Diketopiperazines
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections--drug therapy
HIV Protease Inhibitors--pharmacokinetics
HIV-1--immunology
Humans
Lopinavir
Male
Middle Aged
Piperazines--pharmacokinetics
Pyrimidinones--pharmacokinetics
RNA, Viral--immunology
Receptors, CCR5--therapeutic use
Ritonavir--pharmacokinetics
Spiro Compounds--pharmacokinetics
Young Adult